Huntington's disease (HD) is a hereditary neurodegenerative disorder characterized by brain atrophy particularly in striatum leading to personality changes, chorea and dementia. Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase in the crossroad of many signaling pathways that is highly pleiotropic as it phosphorylates more than hundred substrates including structural, metabolic, and signaling proteins. Increased GSK-3 activity is believed to contribute to the pathogenesis of neurodegenerative diseases like Alzheimer's disease and GSK-3 inhibitors have been postulated as therapeutic agents for neurodegeneration. Regarding HD, GSK-3 inhibitors have shown beneficial effects in cell and invertebrate animal models but no evident efficacy in mouse models. Intriguingly, those studies were performed without interrogating GSK-3 level and activity in HD brain. Here we aim to explore the level and also the enzymatic activity of GSK-3 in the striatum and other less affected brain regions of HD patients and of the R6/1 mouse model to then elucidate the possible contribution of its alteration to HD pathogenesis by genetic manipulation in mice. We report a dramatic decrease in GSK-3 levels and activity in striatum and cortex of HD patients with similar results in the mouse model. Correction of the GSK-3 deficit in HD mice, by combining with transgenic mice with conditional GSK-3 expression, resulted in amelioration of their brain atrophy and behavioral motor and learning deficits. Thus, our results demonstrate that decreased brain GSK-3 contributes to HD neurological phenotype and open new therapeutic opportunities based on increasing GSK-3 activity or attenuating the harmful consequences of its decrease.
Introduction
Huntington's disease (HD) is an inherited neurodegenerative disorder characterized by motor, psychiatric and cognitive symptoms (1). The major site of neuronal loss is the striatum although brain atrophy extents to other regions (1). HD is caused by a CAG triplet expansion in exon 1 of the huntingtin (htt) gene (2) leading to an expanded polyglutamine stretch in the mutant protein. The exact mechanism by which expanded CAG mRNA sequence and/or polyglutamine-induced neurodegeneration remains unknown. However, N-terminal forms of mutant huntingtin (mhtt) are known to accumulate in the cytoplasm and interact with several proteins causing impairment of signaling pathways (3) .
Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase expressed in all tissues, although levels are more abundant in the brain. There are two paralogs of this enzyme, GSK-3α and GSK-3β, which are almost identical, particularly in their catalytic domains (4) , and that are regulated by multiple mechanisms (5) (6) (7) including substrate priming, cellular trafficking, incorporation into protein complexes like axin/APC, D2R/β-arrestin (8, 9) or D2R/Disc1 (10) and post-translational modifications such as phosphorylation at an N-terminal serine residue (Ser 21/9 for α and β, respectively) that renders the kinase inactive in some of its possible functional scenarios (5) . GSK-3 is a pleiotropic enzyme as it is able to phosphorylate more than hundred proteins involved in functions such as metabolism, cell structure, gene expression including epigenetics, and apoptosis (5, 6) .
GSK-3 activity is tuned by self-activating mechanisms (5) and it has been postulated that abnormally increased GSK-3 activity contributes to the pathogenesis of neurodegenerative and psychiatric diseases like Alzheimer's disease (6, 11) and bipolar disorder (12, 13) . Accordingly, the non-selective GSK-3 inhibitor lithium is used as a therapy for bipolar disorder (14) and has been explored in clinical trials for Alzheimer's disease (15, 16) , and selective GSK-3 inhibitors are under development for possible therapeutic interventions (5, (17) (18) (19) .
Regarding HD, GSK-3 inhibition has been shown to protect against polyglutamine-induced cell death and to reduce the number of huntingtin inclusions in cell (20, 21) and invertebrate animal (22, 23) models. However, therapeutic efficacy of GSK-3 inhibition was not evident in rodent models (24) as GSK-3 inhibitors showed beneficial effects only when combined with other drugs (25, 26) particularly those that stimulate autophagy, which may counteract the decreased autophagy elicited by GSK-3 inhibition (27) . However, the main reason for GSK-3 inhibitors not showing a clear beneficial effect by themselves in HD mouse models could be that GSK-3 levels and activity might not be increased in HD. In fact, we and others have previously found increased N-terminal serine phosphorylation of GSK-3 in striatum and other brain regions of various HD mouse models thus suggesting that GSK-3 activity, rather than increased, might be reduced in HD (28) (29) (30) and, although no data are available regarding striatum of postmortem human HD brain, decreased GSK-3β levels have recently been reported in frontal cortex of HD brains (29) . In line with the notion that decreased striatal GSK-3 activity could contribute to HD, transgenic mice with forebrain expression of a dominant-negative form of GSK-3 show reduced GSK-3 activity and increased neuronal apoptosis in the striatum and also motor deficits in striatal-dependent tasks, thus showing an HD-like phenotype (31, 32) .
In the present study, we aim to explore the level and also the enzymatic activity of GSK-3 in the striatum and other affected brain regions of HD patients and mouse models to then elucidate the possible contribution of its alteration to HD pathogenesis by genetic manipulation in mice.
Results

Decreased GSK-3 level and activity in HD brain
To investigate the status of GSK-3 in the brain of HD patients, here we analyzed for the first time the level of GSK-3 in striatum of HD patients and non-affected individuals. By western blot, we observed that levels of both GSK-3 isoforms were dramatically decreased in the striatum of HD brains respect to control brains (P = 0.028 for α and P = 0.045 for β). We also analyzed samples from cortex and hippocampus and a decrease of both isoforms was also observed in cortex (P = 0.006 for α and P = 0.01 for β) while only a tendency to decrease was observed in hippocampus ( Fig. 1A ). As shown in Supplementary Material, Figure S1A -C, no obvious contribution of sex, age or postmortem interval (PMI) is observed to these effects. Interestingly, these decreases in GSK-3α and GSK-3β protein levels in striatum and cortex of HD brains do not seem to be due to altered transcription of the GSK-3α and β genes as quantitative RT-PCR analysis of RNA extracted from HD brains revealed that the transcripts of GSK-3α or β are not diminished in the HD samples ( Fig. 1B) .
As a way to explore whether the observed decrease in GSK-3 protein levels would precede neurodegeneration rather than reflecting a late consequence of the neuronal loss dysfunction, we analyzed the samples with low Vonsattel grade separately. As shown in Supplementary Material, Figure S1D , in this limited number of low-grade HD postmortem brains (Grade 1, n = 1; Grade 2, n = 3), the striatal decrease seems to happen even in the Grade 1 case and the cortical decrease seems to manifest from Grade 2 onwards. This suggests that the observed decrease might predate neurodegeneration rather than just being consequence of the neurodegeneration of the vulnerable cells and preservation of the speared ones.
GSK-3 protein levels are not a direct indicator of GSK-3 activity and, as mentioned, an indirect way to explore GSK-3 activity in some of its possible functional scenarios is by analyzing the levels of phosphorylation of GSK-3 at serine-9 for GSK-3β and at serine-21 for GSK-3α. We thus performed western blot analysis of the inhibitory N-terminal serine phosphorylation of GSK-3 in control and HD samples. However, the previously reported (33) instability of the epitope in human brain tissue associated with postmortem interval, precluded conclusive results. Then, as a direct indicator of activity, we performed an in vitro GSK-3 enzymatic activity assay on homogenates from striatum, cortex and hippocampus of HD patients and controls using a pre-phosphorylated peptide as a well-characterized substrate of GSK-3. In line with the observed decrease in GSK-3 protein levels, we detected a significant decrease in GSK-3 activity in the striatum (73.9%; P = 0.005) and cortex (56.5%; P = 0.001) of HD cases versus controls while only a tendency was observed in hippocampus ( Fig. 1C ). These results indicate that GSK-3 protein levels and activity are decreased in the two most affected brain regions of HD patients.
Decreased GSK-3 levels and activity in the R6/1 mouse model of HD
We and others have previously found increased N-terminal serine phosphorylation of GSK-3 as indicator of reduced GSK-3 activity in selected regions of R6/1 mouse model of HD (28, 29) . To further explore if the results obtained from human HD brain can be recapitulated in this mouse model, we analyzed GSK-3 levels, p-Ser-GSK-3 levels and activity in the striatum, cortex and hippocampus of R6/1 mice at pre-symptomatic ages (4 and 8 weeks), at an early symptomatic age (3.5 months) and at a late symptomatic age (7.5 months). Analysis of GSK-3 protein levels by western blot showed a tendency to decreased GSK-3 level in cortex of 8-week-old R6/1 mice respect WT mice (data not shown) and the earliest significant decreases were found in striatum (P < 0.0001) and cortex (P = 0.006) of early symptomatic (3.5 months) R6/1 mice compared with WT animals ( Fig. 2A and B ). Regarding the hippocampus, a significant decrease in GSK-3 level is found only at late symptomatic stages of the R6/1 mice ( Fig. 2B ). As observed in the brain of HD patients, this decrease was not a consequence of diminished transcript levels as qRT-presymtomatic (8 weeks old) R6/1 mice (data not shown); in striatum (P = 0.049), cortex (P = 0.005) and hippocampus (P = 0.00025) of 3.5-month-old early symptomatic R6/1 mice (Fig. 2D ); and in striatum (P = 0.019), cortex (P = 0.002) and hippocampus (P = 0.009) of 7.5-month-old late symptomatic R6/1 mice compared with WT mice ( Fig. 2E ). These findings were confirmed by immunohistochemistry in striatum and cortex of 3.5-month-old R6/1 mice that show a significant increase in the number of p-Ser-GSK-3α/ β-positive cells (Supplementary Material, Fig. S2A ) and double immunofluorescence with astrocytic (GFAP) or neuronal (NeuN) markers (Supplementary Material, Fig. S2B and C) revealed that the cells with increased p-Ser-GSK-3α/β staining are neurons. Together, the data with the anti-p-Ser-GSK-3α/β antibody further suggest decreased GSK-3 activity in the brain of R6/1 mice.
To confirm that decreased total levels and increased p-GSK-3 indeed result in decreased activity, we performed the GSK-3 enzymatic activity assay on homogenates from striatum, cortex and hippocampus of R6/1 mice. The earliest significant decrease in GSK-3 activity was observed in striatum (23%; P = 0.002) of early symptomatic (3.5 months old) R6/1 mice ( Fig. 2H ) compared with WT and similar results (21.6%; P = 0.006) were observed in late symptomatic (7.5 months old) R6/1 mice ( Fig. 2I) . A tendency to decrease was also observed in cortex and hippocampus of 7.5month-old R6/1 mice ( Fig. 2I ). To try to explain why the decrease in activity assay is restricted to the striatum, we decided to analyze also phosphorylation of GSK-3 at the Tyr216/279 residues which is believed to correlate with activated GSK-3 (5) . As shown in Supplementary Material, Figure S3 , p-Tyr279-GSK-3α and p-Tyr216GSK-3β are significantly decreased only in striatum (P = 0.004 for α and P = 0.028 for β) of R6/1 mice while they are significantly increased in cortex (P = 0.015 for α and P = 0.025 for β) and hippocampus (P = 0.015 for α and P = 0.012 for β) of R6/1 mice. This may be the reason why the decrease in enzymatic activity assay only reaches significance in striatum.
Generation of R6/1 mice with varying levels of transgenic GSK-3
To test whether the observed decreased GSK-3 level and activity in the brain of R6/1 mice contributes to their HD-like phenotype, we decided to explore the consequences of modifying GSK-3 levels by genetic manipulation. For this, we produced R6/1 mice with varying levels of transgenic GSK-3 expression. We have previously generated the BitetO-β-Gal/GSK-3β transgenic mouse line (34) that harbors a DNA construct with a GSK-3β sequence and, as a reporter of gene expression, also a β-galactosidase sequence with a nuclear localization signal. These two coding sequences are under the control of the two CMV minimal promoters (B) Quantitative RT-PCR analysis of GSK-3α and GSK-3β mRNA in striatum and cortex of HD and control samples (n = 5-7 for striatum and n = 9-8 for cortex; only samples with RNA integrity number (RIN) >5 were included in the analysis). (C) In vitro GSK-3 activity assay performed in homogenates from the striatum, cortex and hippocampus of HD patients and control subjects (n = 8 for striatum, n = 10 for cortex and n = 3-9 for hippocampus, Student's t-test; **P < 0.01, *P < 0.05).
(CMVmin) in the bidirectional tetO promoter (BitetO) (Fig. 3A) . These BitetO-β-Gal/GSK-3β mice show a modest expression of the β-Gal reporter in brain areas such as the striatum, cortex or hippocampus ( Fig. 3B ) and of transgenic GSK-3β mRNA ( Fig. 3F ) and only those cells with high levels of the reporter β-Gal show increased GSK-3 levels as evidenced by double β-Gal/GSK-3 immunofluorescence ( Fig. 3C ). In previous characterizations of these mice, no obvious behavioral phenotypes have been observed (35, 36) . Here, we will refer to these animals as LowTgGSK-3 mice. Besides, we have also previously reported that when LowTgGSK-3 mice are combined with mice expressing the tetracycline transactivator (tTA, also known as Tet-Off ) under control of the forebrain neuronal promoter CamKII (CamKII-tTA mice), the resulting double transgenic mice CamKII-tTA + BitetO-β-Gal/GSK-3β ( Fig. 3D ) show robust neuronal expression in all forebrain regions such as the striatum, cortex and hippocampus ( Fig. 3E and F). We will refer to these mice as HighTgGSK-3 mice. These mice have been reported to show increased neuronal cell death, particularly in the hippocampus, and to display Alzheimer's disease-like biochemical and behavioral alterations (34) (35) (36) . In summary, the use of this conditional transgenic mouse system enables the generation of mice with low or high level of GSK-3 transgenic expression.
To generate R6/1 mice with varying levels of transgenic GSK-3 overexpression, we followed the breeding protocol shown in Figure 3G to set HighTgGSK-3 × R6/1 crossing that renders the six experimental genotypes relevant for this study: wild-type (WT), LowTgGSK-3, HighTgGSK-3, R6/1, R6/1 + LowTgGSK-3 and R6/1 + HighTgGSK-3 mice. A total of 270 mice were generated ( Fig. 3G ) that were distributed among the experimental genotypes as follows: WT (n = 53), LowTgGSK-3 (n = 68), HighTgGSK-3 (n = 47), R6/1 (n = 46), R6/1 + LowTgGSK-3 (n = 39) and R6/1 + HighTgGSK-3 (n = 17). They do not follow a Mendelian segregation of genotypes (χ 2 analysis P = 0) as the percentage of R6/1+HighTgGSK-3 mice (5.1%) was lower than expected (12.5%) thus indicating that there is embryonic or perinatal lethality due to the combination of toxicities associated to mhtt and excess of GSK-3 expression in R6/1+HighTgGSK-3 mice.
We then verified by western blot that the decreased GSK-3 levels in striatum of R6/1 mice are progressively corrected by the low-and high-expression transgenes ( Fig. 3H ). A similar effect was observed in the enzymatic activity assay in which the lowand high-expression transgenes counteract the significant decrease observed in the striatum of R6/1 mice respect to WT mice ( Fig. 3I ).
Low transgenic overexpression of GSK-3 attenuates brain atrophy in R6/1 mice
As a global indicator of whether modest or high transgenic expression of GSK-3 would have a positive effect on the progression of the HD phenotype in R6/1 mice, analysis of striatal, cortical and hippocampal volume was performed in sagittal sections obtained from 8-month-old WT, R6/1, R6/1 + LowTgGSK-3 and R6/1 + HighTgGSK-3 mice by using the Cavalieri method ( Fig. 4A and B ). As extensively reported, R6/1 mice presented a reduction in the volume of these brain regions compared with WT mice but, interestingly, R6/1 + LowTgGSK-3 mice showed attenuated atrophy as the volume of cortex (P = 0.0163) and hippocampus (P = 0.0252) was higher compared with R6/1 mice and a tendency was also observed in the striatum ( Fig. 4A and B) . In contrast, no differences were observed between R6/1 and R6/1 + HighTgGSK-3 mice thus indicating that modest GSK-3 overexpression to correct the inherent decrease in R6/1 mice is beneficial but that excessive GSK-3 production is no longer beneficial probably due to the welldocumented neuronal toxicity of excessive GSK-3 activity (34, 37) .
We also analyzed the effect of transgenic GSK-3 expression on the load of Htt-positive aggregates in R6/1 mice. The number and size of aggregates were analyzed in striatum of 8-month-old R6/1, R6/1 + LowTgGSK-3 and R6/1 + HighTgGSK-3 mice by immunostaining with an anti-N-terminal-Htt antibody. We found no changes in the number of striatal inclusions in R6/1 + LowTgGSK-3 and R6/1 + HighTgGSK-3 mice when compared with R6/1 mice ( Fig. 4C and D) . However, there is a tendency to increase the size of the inclusions proportional to the increase in the expression of TgGSK-3 becoming significant in R6/1 + HighTgGSK-3 mice compared with R6/1 mice ( Fig. 4D , P = 0.035).
Low transgenic overexpression of GSK-3 attenuates motor and cognitive deficits in R6/1 mice
We then assessed whether transgenic GSK-3 expression, particularly the moderate one that was able to correct the brain atrophy in R6/1 mice, would also attenuate the motor and cognitive HDlike phenotype of these mice. For this, we first analyzed mice of the six experimental genotypes in the open-field test automated activity cages and found that the hypoactivity observed in R6/1 mice respect to WT mice at 4.5 months of age, as evidenced by a decrease in ambulatory distance and vertical counts, was improved in R6/1+LowTgGSK-3 and R6/1+HighTgGSK-3 mice during the exploratory time (0-5 min) but interestingly only R6/1 +lowTgGSK-3 mice showed improved performance during the 5-15 min test time ( Fig. 5A and B ). Similar results were obtained when male and female mice were analyzed separately (Supplementary Material, Fig. S4 ).
The effect of the GSK-3 transgenes was similar in the accelerating rotarod test. Mice were analyzed at 2, 4, 6 and 8 months of age on the accelerating rotarod (from 4 to 40 rpm) during a 5-min period, in four trials with 1 h inter-trial periods. As expected, all mice expressing mhtt showed a deficit in this motor coordination task from 4 months of age that progressively worsens until the late symptomatic age of 8 months (data not shown). Interestingly, when analyzing the latency to fall as a percentage respect to R6/1 mice, R6/1 + LowTgGSK-3 mice performed significantly the striatum, cortex and hippocampus of 3.5-month-old R6/1 and WT mice and from hippocampus of 7.5-month-old R6/1 and WT mice (n = 7-6 for striatum, n = 7-6 for cortex and n = 7 for hippocampus at 3.5 months old and n = 6-7 for hippocampus of mice at 7.5 months old; Student's t-test; *P < 0.05, **P < 0.01). (B) Quantification of GSK-3α and β levels in A (Student's t-test; *P < 0.05, **P < 0.01). (C) Quantitative RT-PCR analysis of GSK-3α and GSK-3β mRNA in striatum, cortex and hippocampus of 9-month-old R6/1 mice (n = 5). (D) Western blot detection of total p-Ser-GSK-3 levels in homogenates from striatum, cortex and hippocampus of R6/1 and WT mice at 3.5 months of age (n = 7 for striatum, n = 7 for cortex and n = 7 for hippocampus; Student's t-test; **P < 0.01, *P < 0.05). (E) Western blot detection of total p-Ser-GSK-3 levels in homogenates from striatum, cortex and hippocampus of 7.5-month-old R6/1 and WT mice (n = 7 for striatum, n = 7 for cortex and n = 7 for hippocampus; Student's t-test; **P < 0. Student's t-test; **P < 0.01) from R6/1 and WT mice at 3.5 months of age (H) and in striatum, cortex and hippocampus at 7.5 months of age (I) (n = 5-6 for striatum, n = 6-5 for cortex and n = 5 for hippocampus, Student's t-test; **P < 0.01).
better than R6/1 and R6/1 + HighTgGSK-3 mice at 2, 4 and 6 months of age (Fig. 5C ). Similar results were obtained when male and female mice were analyzed separately ( Supplementary  Material, Fig. S4 ).
Finally, we evaluated memory tasks in the six experimental genotypes in the fear conditioning test. More precisely, we performed the context dependent fear conditioning that assesses hippocampal-dependent learning and memory. Figure 5D shows representative plots of freezing/activity of mice of the six experimental genotypes, in dark grey the percentage of time that the mouse spent freezing compared with the percentage of time that the mouse was moving (light grey). As shown in Figure 5E , R6/1 mice show a clear deficit as their percentage of time freezing is dramatically lower when compared with WT. This is most evident in males as it reaches significance for males only and for males + females together but it only shows a tendency for Material, Fig. S4 ). Interestingly, this deficit was attenuated in R6/1 + LowTgGSK-3 mice as they spent significantly more time freezing than R6/1 mice. In summary, these results demonstrate that a moderate increase in GSK-3 expression is able to attenuate both motor and cognitive deficits in R6/1 mice.
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Discussion
Here we analyze for the first time in HD postmortem brain the level and activity of GSK-3 in striatum, the most affected region in this disease, and we also analyzed other affected brain regions like cortex and hippocampus. We found a dramatic decrease in GSK-3 level and activity in striatum and cortex of HD patients and similar results were obtained in the R6/1 mouse model. By combining R6/1 mice with our previously generated transgenic mouse model with conditional overexpression of GSK-3, we are able to demonstrate that the mentioned decrease in GSK-3 does contribute to HD phenotype as the brain atrophy, the locomotor hypoactivity and the deficits in motor coordination and learning of R6/1 mice are attenuated by a moderate expression of transgenic GSK-3.
The first study of GSK-3 in relation to mhtt toxicity was performed in cellular models expressing the Htt exon 1 fragment with 74 glutamines (Q74-Htt) (20) . The non-selective GSK-3 inhibitor lithium, the selective inhibitor SB216763 and the overexpression of a dominant-negative GSK-3 plasmid significantly attenuated Q74-Htt induced cell death. At that time and later, increased GSK-3 levels/activity was reported in Alzheimer's disease (6, (38) (39) (40) (41) (42) and transgenic GSK-3 overexpression in mice had been shown to cause neurodegeneration (34, 35) . Accordingly, GSK-3 inhibitors were postulated to be neuroprotective in multiple cellular and animal models of neurodegeneration (17, (43) (44) (45) . Similarly, treatment with lithium, alone (22) (23) (24) 46, 47) or in combination with valproate (25), or with the selective inhibitor AR-A014418 (22) were neuroprotective in invertebrate and rodent models of HD and of other polyglutamine disorders. In the experiments in which only lithium was administered, with the exception of the R6/2 mice (24) that did not a show a clear improvement, the chemical rat model of HD (46) and the transgenic SCA1 mouse model (47) showed an improvement on motor coordination and cognition. Besides, the invertebrate models also showed attenuated PolyQ-induced cell death (22, 23) . However, all these studies were performed without interrogating whether GSK-3 levels or activity were increased as a consequence of PolyQ expression.
As mentioned, lithium is a non-selective GSK-3 inhibitor as it inhibits many other enzymatic activities such as inositol monophosphatase or histone deacetylase 1 (HDAC1) (48, 49) . Besides, lithium by itself or in combination with other compounds like rapamycin (27) and valproate (25) was found to enhance autophagy and this has been correlated with its beneficial effect on cell and animal models of PolyQ toxicity.
Regarding previous findings about whether GSK-3 activity changes in response to mhtt expression, an increase in the N-terminal phosphorylated form of GSK-3 was first reported in the STHdh Q111/Q111 striatal cells (50) . Since N-terminal phosphorylation of GSK-3 renders it inactive in some functional scenarios, this was suggestive of reduced GSK-3 activity. Similar increase in p-GSK-3 was also reported in the striatum of R6/1 (28) and more recently also in cortex of R6/1 mice (29) and in R6/2 mice (30), although not in KI140 mice (30) . However, no direct analysis of GSK-3 activity had been performed before and only correlation with the level of phosphorylated substrates has been described. Unfortunately, the latter does not provide a clear readout of the kinase activity due to the reported dysregulation in HD of calcineurin (PP2B) (28, 30, 51, 52) and other phosphatases like PHLPP1 (28) or the other major ones PP1 and PP2A (30) . The latter might also play a prominent role in regulating N-terminal phosphorylation of GSK-3 as it is decreased in R6/2 mice which show increased N-terminal phosphorylation of GSK-3 while it is not altered in KI140 mice which do not recapitulate the increase in N-terminal phosphorylation of GSK-3 (30) . In summary, the here reported decrease in total GSK-3 levels, increased p-GSK-3 in its inhibitory epitopes and decreased enzymatic activity is the first solid demonstration of decreased GSK-3 activity in the brain of a mouse model of HD.
Until very recently, there were no reports on the status of GSK-3 in HD patients. As mentioned, the analysis of p-Ser-GSK-3 is hampered by the instability of the epitope and variability with postmortem interval (33) and only total GSK-3 levels had been explored in cortex and cerebellum but not in the striatum, the most affected brain region (29) . Accordingly, the here reported analysis in total GSK-3 levels and enzymatic activity settles that GSK-3 activity is indeed decreased in striatum of HD postmortem brain.
In view of these results, GSK-3-related therapies for HD should not be based on GSK-3 inhibition as initially assumed but on increasing GSK-3 activity. Since no direct activators of GSK-3 are available, such activation could be achieved indirectly by inhibiting kinases such as Akt that are able to phosphorylate GSK-3 at its inhibitory N-terminal serine residue. In fact, Akt (53) . Interestingly, the nonsteroid anti-inflammatory drug celecoxib initially developed as a selective inhibitor of COX-2 is known to also inhibit Akt and this is believed to contribute to its anti-cancer effect (54) and 2,5-dymethyl-elecoxib, a derivative that does not inhibit COX-2 has been shown therapeutically useful in cancer and in mouse models of cardiac hypertrophy by inhibiting Akt and thereby activating GSK-3 (55) .
Another angle for therapeutic implications of this work would be the identification of the mechanism that mediates between the decrease of GSK-3 activity in HD and the phenotype associated with the disease. As it has been described, dominantnegative GSK-3 transgenic mice develop apoptosis and motor deficits showing an HD-like phenotype (31) . It is known that this is mediated by an increase of the FasL/Fas signaling pathway (32, 56) . Accordingly, reduction of FasL signaling might be a way to counteract the harmful consequences of decreased GSK-3 activity in HD. Another GSK-3-associated mechanism might relate to the efficacy of the transport along microtubules. The latter is responsible for recruitment of toxic monomeric or oligomeric mutant proteins into inert inclusion bodies (57) . On the other hand, it has been recently reported an excess of tau in brain of HD patients and mouse models (58) and excess tau results is a less efficient transport along microtubules (59) that can be rescued by increasing GSK-3 activity (60). This might be the reason why the size of mhtt inclusions increases in R6/1 mice with transgenic overexpression of GSK-3. Since this can be protective, pharmacological interventions able to ease transport along microtubules might also be beneficial.
In summary, here we demonstrate that GSK-3 levels and activity are decreased in the striatum of HD patients as well as in other affected brain areas. This is mimicked in the R6/1 mouse model of HD and a moderate increase of GSK-3 in forebrain by genetic manipulation resulted in attenuation of the HD related symptoms of the R6/1 mice thus demonstrating that decreased GSK-3 contributes to HD pathogenesis and offering a new avenue for therapeutic intervention based on approaches that either increase GSK-3 activity or attenuate the effects secondary to the observed GSK-3 decrease.
Materials and Methods
Human brain tissue samples
Brain specimens used in this study from frontal cortex, striatum and hippocampus of HD subjects and controls were provided by Institute of Neuropathology (HUB-ICO-IDIBELL) Brain Bank (Hospitalet de LLobregat, Spain), the Neurological Tissue Bank of the IDIBAPS Biobank (Barcelona, Spain), the Banco de Tejidos Fundación Cien (BT-CIEN, Madrid, Spain) and the Netherlands Brain Bank (Amsterdam, The Netherlands). Written informed consent for brain removal after death for diagnostic and research purposes was obtained from brain donors and/or next of kin. Procedures, information and consent forms have been approved by the Bioethics Subcommittee of Centro Superior de Investigaciones Científicas (Madrid, Spain). The postmortem delay in tissue processing was between 1:00 and 23:30 h (Table 1 ). The neuropathological examination in HD cases revealed a diagnosis of HD grade from 0-1 to 4 following the criteria of Vonsattel (61).
Animals
R6/1 mice transgenic for the human exon-1-Htt gene in B6CBAF1 background (62) and GSK-3 overexpression transgenic mice in the B6 background previously generated (34) were used. All mice were housed at the Centro de Biología Molecular "Severo Ochoa" animal facility. Mice were housed four per cage with food and water available ad libitum and maintained in a temperaturecontrolled environment on a 12/12 h light-dark cycle with light onset at 07:00 h. Animal housing and maintenance protocols followed the guidelines of Council of Europe Convention ETS123, recently revised as indicated in the Directive 86/609/EEC. Animal experiments were performed under protocols (P15/P16/P18/P22) approved by the Centro de Biología Molecular Severo Ochoa 
Western blot
The samples from different human brain regions that were stored at −80°C were ground with a mortar in a frozen environment with liquid nitrogen to prevent thawing of the samples. The resulting powder was homogenized. For mouse, brains were quickly dissected on an ice-cold plate. Both extracts were prepared by homogenizing the brain areas in ice-cold extraction buffer consisting of 20 m HEPES, pH 7.4, 100 m NaCl, 20 m NaF, 1% Triton X-100, 1 m sodium orthovanadate, 1 μ okadaic acid, 5 m sodium pyrophosphate, 30 m β-glycerophosphate, 5 m EDTA and protease inhibitors (2 m PMSF, 10 µg/ml aprotinin, 10 µg/ml leupeptin and 10 µg/ml pepstatin 
Gsk-3 activity assay
Tissue was homogenized in 20 m HEPES, pH 7.4, 100 m NaCl, 10 m NaF, 1 m VO 4 Na, 1% Triton X-100, 1 m EDTA, 1 m EGTA supplemented with a cocktail of protease inhibitors (Roche). Supernatants were collected after centrifugation at 14 000 × g for 15 min. The GS1 peptide (YRRAAVPPSPSLSRHSSPHQ-S * EDEE) with phosphorylated ser21 was used as substrate (63) . Supernatants were incubated at 37°C with GS1 peptide and [γ-32 P] ATP in 25 m Tris-HCl, pH 7.5, 1 m DTT, 10 m MgCl 2 and either 10% DMSO or 100 µ m AR-A014418 (selective GSK-3 inhibitor). The assays were stopped by spotting aliquots on P81 phosphocellulose as described (36) . GSK-3 activity was calculated as the difference between the activity in the presence of DMSO and the activity in the presence of AR-A014418.
Immunohistochemistry and immunofluorescence
Mice were sacrificed using CO 2 
Stereological quantification of brain volume and huntingtin aggregates
Diaminobenzidine immunohistochemistry was performed as previously described (64) . Tissue was incubated with the primary antibodies anti-DARPP32 1 : 1000 (611520 from BD Bioscience) or anti-EM48 1 : 100 (MAB5374 from Millipore), followed by the corresponding biotinylated secondary antibody 1 : 200 (Thermo Fisher). For estimation of cortical, striatal and hippocampal volumes, 12 sagittal sections per animal spaced 240 μm apart were examined. Unbiased blinded to genotype counting was performed with Computer-Assisted Stereology Toolbox (CAST) software (Olympus Danmark A/S, Ballerup, Denmark). Automated quantification of the number and size of huntingtin aggregates within the striatum was performed using CellProfiler v2.8 software. Briefly, five sagittal striatal sections per animal spaced 240 μm apart were chosen for the analysis. Images from the 100% of the striatum were acquired at ×20 magnification and EM48 staining was used to identify nuclear inclusions and delimitate their area. The CellProfiler pipeline file containing the specific parameters of the automated quantification is available upon request.
Behavioral testing
Open field test Locomotor activity was measured at the age of 4.5 months in clear plexiglas boxes measuring 43.2× 43.2 cm, outfitted with photobeam detectors for monitoring horizontal and vertical activity. Activity levels were recorded with an MED Associates' Activity Monitor (MED Associates, St Albans, VT, USA). Locomotor activity data were collected via a PC and was analyzed with the MED Associates' Activity Monitor Data Analysis software. Mice were placed in a corner of the open-field apparatus and left to move freely. Variables recorded included ambulatory distance (cm) and vertical counts. Data were individually recorded for each animal during 15 min. The number of animals used for this test was WT, n = 19 (males n = 8, females n = 11); LowTgGsk-3, n = 22 (males n = 10, females n = 12); HighTgGsk-3, n = 13 (males n = 3, females n = 10); R6/1, n = 19 (males n = 6, females n = 13); R6/1 + LowTgGsk-3, n = 17 (males n = 8, females n = 9); R6/1 + HighTgGsk-3, n = 7 (males n = 2, females n = 5).
Rotarod test
Rotarod test was performed at the age of 2, 4, 6 and 8 months with accelerating rotarod apparatus (Ugo Basile). Mice were pretrained during two days at a constant speed, 4 rpm the first day over 1 min four times or 8 rpm over 1 min four times the second day. On the third day, rotarod was set to accelerate from 4 to 40 rpm over 5 min and mice were tested four times. During accelerating trials, the latency to fall from the rod was measured. The number of animals used for this test was: R6/1, n = 35 (males n = 11, females n = 24); R6/1 + LowTgGsk-3, n = 26 (males n = 12, females n = 14); R6/1 + HighTgGsk-3, n = 12 (males n = 6, females n = 6).
Contextual fear conditioning test
The test was performed at the age of 5 months using the Startfear 1.06 system for fear conditioning from Panlab. During training, mice stayed in the conditioning chamber for a total of 6 min 30 s. After 2 min of exploration, an 85 dB sound was emitted for 30 s and a 0.2 mA foot-shock was superposed to the tone during the last 2 s (three times). Thirty seconds after the last foot-shock, the mouse was removed from the chamber and returned to its home cage. Twenty-four hours after the conditioning session, the contextual memory was assessed by introducing the mouse in the conditioning chamber. The behavioral index use to quantify the memory of context conditioning is freezing, a speciesspecific tonic immobility response. Freezing is defined as a tonic immobilization, with total absence of movement except those due to breathing. Freezing scores were assessed during 6 min, no tone or foot-shock being presented to the animal during this test. The number of animals used for this test was: WT, n = 32 (males n = 5, females n = 27); LowTgGsk-3, n = 32 (males n = 19, females n = 13); HighTgGsk-3, n = 22 (males n = 5, females n = 17); R6/1, n = 27 (males n = 8, females n = 19); R6/1 + LowTgGsk-3, n = 26 (males n = 12, females n = 14); R6/1 + HighTgGsk-3, n = 10 (males n = 6, females n = 4).
